Inhibition of protease activity in cultures of rous sarcoma virus-transformed cells: effect on the transformed phenotype.
We have examined the role of proteolytic activity in the genesis and maintenance of the transformed phenotype by growing cultures of chick embryo fibroblasts transfromed by Rous sarcoma virus either in medium containing plasminogen-free serum or in medium to which protease inhibitors were added. Alterations in morphology, adhesiveness, and hexose transport were used as markers for the transformed state. Addition of the trypsin inhibitors NPGB or Soy Bean Trypsin Inhibitor at concentrations which inhibited transformation-associated fibrinolysis restored adhesiveness and morphology to near normal, but did not affect the rate of hexose transport. Growth of Rous-infected cells in plasminogen-free medium blocked the appearance of morphological and adhesive alterations, but allowed the rate of hexose transport to increase to the transformed level. Thus we were able to separate the appearance of transformation-specific changes in morphology and adhesiveness (which apparently require fibrinolytic activity) from the increased rate of hexose transport (which is independent of fibrinolytic activity). Another trypsin inhibitor, TLCK, although it did not inhibit fibrinolysis, was very effective at restoring adhesiveness and morphology as well as hexose transport to normal. This raises the possibility that there is another, perhaps earlier, protease involved in the genesis of the transformed phenotype.
D000818:Animals; D001358:Avian Sarcoma Viruses; D001693:Biological Transport, Active / Q000187:drug effects; D002448:Cell Adhesion / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002471:Cell Transformation, Neoplastic / Q000187:drug effects*; D002478:Cells, Cultured; D002642:Chick Embryo; D003513:Cycloheximide / Q000494:pharmacology; D003847:Deoxyglucose / Q000378:metabolism; D005342:Fibrinolysis / Q000187:drug effects; D005347:Fibroblasts; D008239:Lysine / Q000031:analogs & derivatives*; D010641:Phenotype; D010958:Plasminogen / Q000494:pharmacology; D011480:Protease Inhibitors; D014176:Protein Biosynthesis; D014107:Tosyllysine Chloromethyl Ketone / Q000494:pharmacology*; D014361:Trypsin Inhibitors / Q000494:pharmacology
D011480:Protease Inhibitors; D014361:Trypsin Inhibitors; D014107:Tosyllysine Chloromethyl Ketone; D010958:Plasminogen; D003513:Cycloheximide; D003847:Deoxyglucose; D008239:Lysine